Professor Amin Rostami PharmD, PhD, FCP

2011

• Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2011). Recommended strategies for investigating cytochrome P450 contributions on the candidate metabolism at drug discovery stage: Applications for the reaction phenotyping. Presented at 4th Asian Pacific Regional ISSX Meeting. Tainan, Taiwan. eScholarID:106464
• Hatley O, Jones C, Galetin A and Rostami-Hodjegan, A. (2011). Methodology Optimisation in Intestinal Microsome Preparation: Implications for Scaling Approaches?. Presented at 17th North American Regional ISSX Meeting. USA. eScholarID:147601
• Hatley O, Jones C, Galetin A and Rostami-Hodjegan, A. (2011). Methodology Optimisation in Intestinal Microsome Preparation: Implications for Scaling Approaches?. Presented at AAPS Meeting, Washington. USA. eScholarID:147603
• Johnson TN, Rowland-Yeo K, Rostami-Hodjegan A. (2011). Predicting the pharmacokinetic (PK) of Theophylline (Theo) and its interaction with Fluvoxamine (Fluv) in liver cirrhosis (CIRR). Presented at ASCPT. Dallas, USA. eScholarID:106465
• Rowland-Yeo K, Ghobadi C, Rostami-Hodjegan A. (2011). Prediction of the increase in systematic exposure of Paroxetine in patients with renal impairment. Presented at ASCPT. Dallas, USA. eScholarID:106469
• Hatley O, Jones C; Galetin A and Rostami-Hodjegan A. (2011). Methodology optimisation in intestinal microsome preparation: Implications for scaling approaches. Presented at DRUG METAB REV. eScholarID:147634
• •Lu G, Abduljalil K, Jamei M, Johnson TN, Soltani H, Rostami-Hodjegan A. (In-press). PBPK Models for Assessing the Kinetics of Xenobiotics during Pregnancy: Achievements and Shortcomings. Curr Drug Metab, eScholarID:130454
• Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A. Soltani H. (In-press). Anatomical and Changes with Gestational Age during normal Pregnancy: A Database for Parameters Required in Physiologically Based Pharmacokinetic Modelling. Clin Pharmacokin, eScholarID:138967
• Achour B, Barber J, Rostami-Hodjegan A. (2011). Cytochrome P450 Pig Liver Pie. Drug Metab and Dispos, 39(11), 1-5. eScholarID:130456
• Barter ZE, Perrett HF, Rowland Yeo K, Allorge D, Lennard MS, Rostami-Hodjegan A. (2011). Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharm & Drug Dispos, 31(8-9), 516-532. eScholarID:95957
• Crewe KH, Barter Z, Rowland-Yeo K, Rostami-Hodjegan A. (2011). Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into Inter System Extrapolation Factors. Biopharm & Drug Dispos, 32(6), 303-18. eScholarID:130458 | DOI:10.1002/bdd.760
• Cubitt HE, Rowland-Yeo K, Howgate EM, Rostami-Hodjegan A, Barter ZE. (2011). Sources of inter-individual variability in IVIVE of clearance. An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica, 48(4), 623-638. eScholarID:130462
• Ghobadi C, Johnson TN, Aarabi M, Almond LM, Alabi A, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A. (2011). Application of systems approach to bottom-up asessment of pharmacokinetics in obese patients: Expected variations in clearance. Clinical Pharmacokinetics, 50(12), 809-822. eScholarID:130457 | DOI:10.2165/11594420-000000000-00000
• Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. (2011). Critique of the two-fold measure of prediction success for ratios:application for the assessment of drug-drug interactions. Drug Metab Dispos, 39(2), 170-173. eScholarID:95952 | DOI:10.1124/dmd.110.036103
• Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB, Galetin A. (2011). Assessment of Algorithms for Predicting Drug-Drug Interactions via Inhibition Mechanisms: Comparison of Dynamic and Static Models. Br J Clin Pharmacol, 71(1), 72-87. eScholarID:95959 | DOI:10.1111/j.1365-2125.2010.03799.x
• Johnson TN, Rostami-Hodjegan A. (2011). Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: Parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Pediatric Anesthisia, 21(3), 291-301. eScholarID:82519 | DOI:10.1111/j.1460-9592.2010.03323.x
• Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. (2011). The Proton Pump Inhibitor; Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metab Dispos, 39(11), 1-14. eScholarID:130455
• Ohtani H, Barter Z , Minematsu T, Makuuchi M, Sawada Y, Rostami-Hodjegan A. (2011). Haematocrit as a covariate for tacrolimus pharmacokinetics in liver transplant patients: Bottom-up modelling and simulation to assess study power. Biopharm & Drug Dispos, 32(9), 498-506. eScholarID:138968
• Pang KS, Rostami-Hodjegan A, Dan L. (In-press). Fraction absorbed (Fabs): Different connotations and confusion in the literature? Biopharm & Drug Dispos, eScholarID:130459
• Rowland-Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. (2011). Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol, 4(2), 261-274. eScholarID:130463 | DOI:10.1586/ecp.10.143
• Rowland-Yeo K, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT. (2011). Prediction of time-dependant CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: Impact of inactivation parameters and enzyme turnover. Eur J Clin Pharm Sci, 43(3), 160-173. eScholarID:130460 | DOI:10.1016/j.ejps.2011.04.008

2010

• Almond LM, Abduljalil K, Rowland-Yeo K, Rostami-Hodjegan A. (2010). Simulation of virtual human subjects to investigate the impact of. Presented at FIP Pharmaceutical Sciences 2010 World Congress. New Orleans, USA. eScholarID:106473
• Hatley O, Jones C, Galetin A and Rostami-Hodjegan A. (2010). Extrapolation of in vitro intestinal clearance: establishing validated subcellular fraction scaling factors. Presented at DMDG Meeting. Canterbury. eScholarID:107123
• Lu G, Abduljalil K, Furness P, Jamei M, Rostami-Hodjegan A, Soltani H. (2010). A time-varying physiologically-based pharmacokinetic model of caffeine during pregnancy. Presented at Drug Metabolism Discussion Group Meeting. Canterbury, UK. eScholarID:108973
• Mishra H, Jamei M, Rowland-Yeo K, Rostami-Hodjegan A. (2010). Prediction of human intestinal metabolism of CYP3A substrates using the Advanced, Dissolution, Absorption and Metabolism (ADAM) Model. Presented at 11th Annual Simcyp Consortium Meeting. Sheffield, UK. eScholarID:108972
• Pade D, Harwood M, Turner D, Jamei M, Rostami-Hodjegan A. (2010). Prediction of Vss and tissue concentration-time profiles for four benzodiazepines using physicochemical, in vitro and experimental data in rat using a mechanistic PBPK model. Presented at 11th Annual Simcyp Consortium Meeting. Sheffield, UK. eScholarID:108968
• Pade D, Harwood M, Turner D, Jamei M, Rostami-Hodjegan A. (2010). Prediction of Vss and tissue concentration-time profiles for four benzodiazepines using physicochemical, in vitro and experimental data in rat using a mechanistic PBPK model. Presented at FIP Pharmaceutical Sciences 2010 World Congress. New Orleans, USA. eScholarID:106471
• Salem F, Johnson TN, Rostami-Hodjegan A. (2010). Predicting pharmacokinetics for two NSAIDs commonly used in paediatrics using a physiologically-based model: comparing in vitro data, in vivo data from adults, or their combination as input parameters. Presented at CAPKR Annual Research Meeting. Manchester, UK. eScholarID:108975
• (2010). Drug clearance in different in vitro systems as a preliminary indicator of hepatic uptake. Presented at 9th International ISSX Meeting. Istanbul, Turkey. eScholarID:96043
• Johnson TN, Boussery K, Tucker GT, Rostami-Hodjegan A. (2010). A semi mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokin, 49(3), 189-206. eScholarID:95963 | DOI:10.2165/11318160-000000000-00000
• Kay L, Survana K, Scola AM, Rostami-Hodjegan A, Chess-Williams R, Peachell P. (2010). Influence of beta2-adrenoceptor gene polymorphisms on beta2-adrenoceptor in human lung. Pulmonary Pharmacology and Therapeutics, 23, 71-77. eScholarID:77139 | DOI:10.1016/j.pupt.2009.10.013
• Polasek TM, Polak S, Doogue MP, Rostami-Hodjegan A, Miners JO. (2010). Assessment of inter-individual variability in predicted phenytoin clearance. Eu J Clin Pharm, 65, 1203-1210. eScholarID:77144
• Rowland-Yeo K, Jamei M, Yang J, Rucker GT, Rostami-Hodjegan A. (2010). Physiologically-based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut – the effect of diltiazem on the time-course of exposure to triazolam. Eu J Pharm Sci, 39(5), 298-309. eScholarID:82520 | DOI:10.1016/j.ejps.2009.12.002

2009

• Guest EJ, Rowland Yeo K, Rostami-Hodjegan A, Tucker GT, Houston JB and Galetin A. (2009). Assessment of Algorithms for Predicting Drug-Drug Interactions via Inhibition Mechanisms. Presented at Drug Metabolism Discussion Group (DMDG) Meeting. Cambridge. eScholarID:107126
• Neuhoff S, Barter ZE, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. (2009). Extrapolation on the in vitro drug clearance by UGT1A1 to predict in vivo glucuronidation: Scaling factors for the use of recombinant system. Presented at PharmSciFair. Nice, France. eScholarID:108980
• Polak S, Ahamadi M, Ghobadi C, Mishra H, Jamei M, Rostami-Hodjegan A. (2009). Prediction of human pharmacokinetics following dermal administration: integration of a skin absorption module to the Simcyp Population-Based ADME Simulator with the aim of avoiding animal studies. Presented at 7th World Congress on Alternative & Animal Use in the Life Sciences. Rome, Italy. eScholarID:106444
• Salem F, Barter ZE, Johnson TN, Rostami-Hodjegan A. (2009). Comparison of in vitro and in vivo metabolic clearance estimates for the prediction of caffeine and theophylline pharmacokinetics in adults, children and neonates using a physiologically based model. Presented at Drug Metabolism Discussion Group Meeting. Cambridge, UK. eScholarID:108977